LB1. Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
Session: Oral Abstract Session: Late Breaker Oral Abstracts: HIV and Antibiotic Trials
Thursday, October 4, 2018: 10:30 AM
Room: S 151-153

Background:

Doravirine (DOR) is a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI). In the phase 3 DRIVE-AHEAD trial in HIV-1 infected treatment-naïve adults, DOR demonstrated non-inferior efficacy to efavirenz (EFV) and favorable profiles for neuropsychiatric tolerability and lipids at 48 weeks. We present data through week 96.

Methods:

DRIVE- AHEAD (Clinical Trials Registration: NCT02403674) is a phase 3, multicenter, double-blind, non-inferiority trial that compared DOR with EFV. Eligible participants were HIV-1 infected treatment-naïve adults with pre-treatment HIV-1 RNA ≥1,000 c/mL. Participants were randomized (1:1) to a fixed-dose regimen of DOR 100mg, lamivudine 300mg and tenofovir disoproxil fumarate 300mg (DOR/3TC/TDF) QD or EFV 600mg, emtricitabine 200mg and TDF 300mg (EFV/FTC/TDF) QD for up to 96 weeks. Randomization was stratified by screening HIV-1 RNA (≤/>100,000 c/mL) and hepatitis B/C co-infection (yes/no). The efficacy endpoint of interest at week 96 was HIV-1 RNA <50 c/mL with predefined non-inferiority margin of 10%. Safety endpoints of interest included occurrence of pre-specified neuropsychiatric adverse events and mean change from baseline in fasting lipid levels at week 96. 

Results:

Of 734 participants randomized, 728 received study drug and were included in analyses (mean age 33 yr, 85% male, 48% white, 19% black, 34% Hispanic). At week 96, HIV-1 RNA <50 c/mL was achieved by 77.5% of DOR/3TC/TDF recipients vs 73.6% of EFV/FTC/TDF recipients (difference 3.8%, 95%CI [-2.4, 10.0]). No additional phenotypic resistance to DOR was observed between weeks 48 and 96, while 2 additional participants in the EFV/FTC/TDF group developed resistance to EFV. Dizziness, sleep disorders/disturbances, altered sensorium, and rash were less frequent in DOR/3TC/TDF recipients than in EFV/FTC/TDF recipients. Fasting LDL-C and non-HDL-C increased in the EFV/FTC/TDF group but not in the DOR/3TC/TDF group, while change in total cholesterol/HDL-C ratio was similar.

 

Conclusion:

Week 96 results support non-inferiority of DOR/3TC/TFD to EFV/FTC/TDF established at Week 48 with no additional DOR resistance between week 48 and 96. DOR/3TC/TDF was safe and well-tolerated with fewer neuropsychiatric and rash events and favorable lipid profile compared with EFV/FTC/TDF.

Chloe Orkin, MBBCh1, Kathleen Squires, MD2, Jean-Michel Molina, MD3, Paul Sax, MD4, Wingwai Wong, MD5, Otto Sussmann, MD6, Gina Lin, MS7, Sushma Kumar, PhD7, George Hanna, MD7, Carey Hwang, MD, PhD7, Elizabeth Martin, DO, MPH7 and Hedy Teppler, MD8, (1)Department of Infection and Immunity, Royal London Hospital and Queen Mary University, Barts Health NHS Trust, London, United Kingdom, (2)Sidney Kimmel Medical College of Thomas Jefferson University Philadelphia, Philadelphia, PA, (3)Department of Infectious Diseases, University of Paris Diderot, Sorbonne Paris Cité; Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France, (4)Brigham and Women's Hospital, Boston, MA, (5)Taipei Veterans General Hospital, Taipei, Taiwan, (6)Infectious Diseases, Hospital San Rafael De Tunja, Tunja, Colombia, (7)Merck & Co., Inc., Kenilworth, NJ, (8)Merck, Upper Gwynedd, PA

Disclosures:

C. Orkin, AbbVie, Abbott, Boehringer Ingelheim, BMS, Gilead, GSK, Janssen, ViiV: Grant Investigator and Research Contractor , Research grant and Research support .

K. Squires, Merck & Co., Inc.,: Ad Board , Ad Board . Gilead Sciences: Grant , Ad Board . VIIV: Ad Board , Ad Board . Bristol Myers Squibb: Ad Board , Ad Board . Janssen: Ad Board , Ad Board .

J. M. Molina, Gilead: Scientific Advisor , Consulting fee . Merck: Scientific Advisor , Consulting fee . ViiV: Scientific Advisor , Consulting fee . Teva: Scientific Advisor , Consulting fee .

P. Sax, Gilead: Consultant and Grant Investigator , Consulting fee , Grant recipient and Research grant . ViiV Healthcare: Consultant and Grant Investigator , Consulting fee , Grant recipient and Research grant . Merck: Consultant and Grant Investigator , Consulting fee , Grant recipient and Research grant . Janssen: Consultant , Consulting fee . BMS: Grant Investigator , Grant recipient and Research grant .

W. Wong, Merck & Co., Inc.: Research Contractor , Research grant .

O. Sussmann, None

G. Lin, Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc.: Employee and Shareholder , May hold stock/stock options in the company and Salary .

S. Kumar, Merck & Co., Inc.,: Employee and Shareholder , Salary .

G. Hanna, Merck & Co., Inc.,: Employee and Shareholder , Salary .

C. Hwang, Merck & Co., Inc.,: Employee and Shareholder , Salary .

E. Martin, Merck & Co., Inc.,: Employee and Shareholder , Salary .

H. Teppler, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA: Employee , May hold stock/stock options in the company and Salary .

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.